Literature DB >> 19294362

Optimal dosing of renin-angiotensin-aldosterone system blockers for renal protection: a solved issue?

G D Laverman, S J L Bakker, G J Navis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19294362     DOI： 10.1007/s00125-009-1328-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  5 in total

1.  The COOPERATE trial: a letter of concern.

Authors:  Regina Kunz; Marcel Wolbers; Tracy Glass; Johannes F E Mann
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321

2.  Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?

Authors:  Liffert Vogt; Gerjan Navis; Dick de Zeeuw
Journal:  J Am Soc Nephrol       Date:  2005-03       Impact factor: 10.121

3.  Dual renin-angiotensin system blockade at optimal doses for proteinuria.

Authors:  Gozewijn D Laverman; Gerjan Navis; Robert H Henning; Paul E de Jong; Dick de Zeeuw
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

4.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321

5.  Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.

Authors:  K J Schjoedt; A S Astrup; F Persson; E Frandsen; F Boomsma; K Rossing; L Tarnow; P Rossing; H-H Parving
Journal:  Diabetologia       Date:  2008-10-31       Impact factor: 10.122
  5 in total
  1 in total

1.  Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial.

Authors:  F Persson; P Rossing; H Reinhard; T Juhl; C D A Stehouwer; C Schalkwijk; A H J Danser; F Boomsma; E Frandsen; H-H Parving
Journal:  Diabetologia       Date:  2010-05-18       Impact factor: 10.122
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.